SEC Comment Letter 0000000000-24-001771 to Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc.
Date: Feb. 14, 2024 · CIK: 0001892500 · Accession: 0000000000-24-001771
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276913
Letter
United States securities and exchange commission logo February 14, 2024 Dr. Adi Zuloff-Shani Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re:Clearmind Medicine Inc. Registration Statement on Form F-1 Filed February 7, 2024 File No. 333-276913 Dear Dr. Adi Zuloff-Shani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Huberman, Esq.
Show Raw Text
United States securities and exchange commission logo
February 14, 2024
Dr. Adi Zuloff-Shani
Chief Executive Officer
Clearmind Medicine Inc.
101 – 1220 West 6th Avenue
Vancouver, British Columbia V6H1A5
Re:Clearmind Medicine Inc.
Registration Statement on Form F-1
Filed February 7, 2024
File No. 333-276913
Dear Dr. Adi Zuloff-Shani:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David Huberman, Esq.